Opti.Cd

OPTI.CD's capital structure is characterized by a debt-to-equity ratio of 0.99, indicating a relatively balanced mix of debt and equity financing. However, the company's liquidity position is weak, as evidenced by a current ratio of 0.22 and negative free cash flow of -2,850,060 CAD. The company's cash and equivalents amount to only 5,000 CAD, which is significantly lower than its long-term debt of 6,518,920 CAD, resulting in a net cash position that is negative after subtracting total debt.

In terms of profitability, OPTI.CD is currently unprofitable, with a net income of -3,712,030 CAD and an operating income of -3,726,350 CAD. The company's return on equity is -0.5649, and its return on assets is -0.244, both of which are significantly below the industry median for pharmaceutical companies. These metrics suggest that the company is not generating sufficient returns to cover its cost of capital or to justify its asset base.

OPTI.CD's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no geographic diversification provided in the available data. This lack of diversification increases the company's exposure to market-specific risks, particularly in the pharmaceuticals industry where regulatory and reimbursement environments can vary significantly by region.

The company's growth trajectory is uncertain, as it has not provided specific revenue outlook figures for the current or next fiscal year. However, the negative operating and net income figures, combined with the company's high debt load and weak liquidity, suggest that the company may face challenges in achieving sustainable growth in the near term. The capital expenditure of -88,380 CAD indicates that the company is not investing heavily in new projects or infrastructure, which could further limit its growth potential.

The risk assessment for OPTI.CD highlights several key concerns. The company's liquidity risk is rated as medium, primarily due to its negative free cash flow and low cash reserves. The dilution risk is rated as low, with no immediate pressure for additional equity issuance. However, the company's negative net income and high debt load could increase the likelihood of dilution in the future if the company requires additional capital to fund operations or debt service.

Recent events related to OPTI.CD include the filing of its latest financial statements, which disclose the company's current financial position and performance. No recent earnings call transcripts or other material events have been provided in the available data. The company's ongoing development and commercialization of prescription eye drops remain its primary business focus, with no significant changes in strategy or product pipeline disclosed.